 Selective Estrogen Receptor Modulators
"Selective Estrogen Receptor Modulators" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A structurally diverse group of compounds distinguished from ESTROGENS by their ability to bind and activate ESTROGEN RECEPTORS but act as either an agonist or antagonist depending on the tissue type and hormonal milieu. They are classified as either first generation because they demonstrate estrogen agonist properties in the ENDOMETRIUM or second generation based on their patterns of tissue specificity. (Horm Res 1997;48:155-63)
| Descriptor ID |
D020845
|
| MeSH Number(s) |
D06.347.360.827 D27.505.696.399.450.360.827
|
| Concept/Terms |
Selective Estrogen Receptor Modulators- Selective Estrogen Receptor Modulators
- SERMs
- Selective Estrogen Receptor Modulator
- Estrogen Receptor Modulator, Selective
- Estrogen Receptor Modulators, Selective
- SERM
|
Below are MeSH descriptors whose meaning is more general than "Selective Estrogen Receptor Modulators".
Below are MeSH descriptors whose meaning is more specific than "Selective Estrogen Receptor Modulators".
This graph shows the total number of publications written about "Selective Estrogen Receptor Modulators" by people in this website by year, and whether "Selective Estrogen Receptor Modulators" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 0 | 1 | 1 | | 2001 | 0 | 1 | 1 | | 2002 | 0 | 1 | 1 | | 2003 | 1 | 1 | 2 | | 2004 | 2 | 1 | 3 | | 2005 | 1 | 1 | 2 | | 2009 | 1 | 0 | 1 | | 2011 | 1 | 0 | 1 | | 2013 | 1 | 2 | 3 | | 2015 | 0 | 2 | 2 | | 2016 | 1 | 1 | 2 | | 2018 | 1 | 1 | 2 | | 2021 | 1 | 1 | 2 | | 2022 | 0 | 2 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Selective Estrogen Receptor Modulators" by people in Profiles.
-
Ren P, Tiede C, Fanning SW, Adams T, Speirs V, Nelson ER, Cheng C, Moore TW, Greene GL, Tomlinson D, Selvin PR. Labeling of a mutant estrogen receptor with an Affimer in a breast cancer cell line. Biophys J. 2022 10 04; 121(19):3651-3662.
-
Hosfield DJ, Weber S, Li NS, Sauvage M, Joiner CF, Hancock GR, Sullivan EA, Ndukwe E, Han R, Cush S, Lainé M, Mader SC, Greene GL, Fanning SW. Stereospecific lasofoxifene derivatives reveal the interplay between estrogen receptor alpha stability and antagonistic activity in ESR1 mutant breast cancer cells. Elife. 2022 05 16; 11.
-
Lainé M, Fanning SW, Chang YF, Green B, Greene ME, Komm B, Kurleto JD, Phung L, Greene GL. Lasofoxifene as a potential treatment for therapy-resistant ER-positive metastatic breast cancer. Breast Cancer Res. 2021 05 12; 23(1):54.
-
Raheem OA, Chen T, Akula KP, Greenberg J, Le TV, Chernobylsky D, Sikka SC, Walsh TJ. Efficacy of Non-Testosterone-Based Treatment in Hypogonadal Men: A Review. Sex Med Rev. 2021 07; 9(3):381-392.
-
Fanning SW, Jeselsohn R, Dharmarajan V, Mayne CG, Karimi M, Buchwalter G, Houtman R, Toy W, Fowler CE, Han R, Lainé M, Carlson KE, Martin TA, Nowak J, Nwachukwu JC, Hosfield DJ, Chandarlapaty S, Tajkhorshid E, Nettles KW, Griffin PR, Shen Y, Katzenellenbogen JA, Brown M, Greene GL. The SERM/SERD bazedoxifene disrupts ESR1 helix 12 to overcome acquired hormone resistance in breast cancer cells. Elife. 2018 11 29; 7.
-
Fanning SW, Hodges-Gallagher L, Myles DC, Sun R, Fowler CE, Plant IN, Green BD, Harmon CL, Greene GL, Kushner PJ. Specific stereochemistry of OP-1074 disrupts estrogen receptor alpha helix 12 and confers pure antiestrogenic activity. Nat Commun. 2018 06 18; 9(1):2368.
-
Singhal H, Greene ME, Tarulli G, Zarnke AL, Bourgo RJ, Laine M, Chang YF, Ma S, Dembo AG, Raj GV, Hickey TE, Tilley WD, Greene GL. Genomic agonism and phenotypic antagonism between estrogen and progesterone receptors in breast cancer. Sci Adv. 2016 06; 2(6):e1501924.
-
Nelson ER. Detection of Endogenous Selective Estrogen Receptor Modulators such as 27-Hydroxycholesterol. Methods Mol Biol. 2016; 1366:431-443.
-
Vachon CM, Schaid DJ, Ingle JN, Wickerham DL, Kubo M, Mushiroda T, Goetz MP, Carlson EE, Paik S, Wolmark N, Nakamura Y, Wang L, Weinshilboum R, Couch FJ. A polygenic risk score for breast cancer in women receiving tamoxifen or raloxifene on NSABP P-1 and P-2. Breast Cancer Res Treat. 2015 Jan; 149(2):517-23.
-
Constantine GD, Goldstein SR, Archer DF. Endometrial safety of ospemifene: results of the phase 2/3 clinical development program. Menopause. 2015 Jan; 22(1):36-43.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|